ProMIS Neurosciences ROCE
Quel est le ROCE de ProMIS Neurosciences?
Le ROCE de ProMIS Neurosciences, Inc. est -49.45%
Quelle est la définition de ROCE?
Le retour sur capital utilisé (ROCE) est un ratio financier qui mesure la rentabilité d'une entreprise et l'efficacité avec laquelle son capital est utilisé.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE des entreprises dans Health Care secteur sur OTC par rapport à ProMIS Neurosciences
Que fait ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Entreprises avec roce similaire à ProMIS Neurosciences
- Genasys Inc a ROCE de -49.78%
- Hookipa Pharma Inc a ROCE de -49.72%
- Choom a ROCE de -49.69%
- ANGLE Plc a ROCE de -49.52%
- 4SC AG a ROCE de -49.47%
- Beyond Meat Inc a ROCE de -49.46%
- ProMIS Neurosciences a ROCE de -49.45%
- Shineco Inc a ROCE de -49.44%
- Calliditas Therapeutics AB (publ) a ROCE de -49.42%
- AUX Resources a ROCE de -49.38%
- Argenica Therapeutics a ROCE de -49.26%
- Rice Acquisition a ROCE de -49.24%
- Digimarc a ROCE de -49.11%